Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - November 2013


Clinical Trials in CNS

18 Nov 2013 - 19 Nov 2013 - London, UK



Bookmark and Share


SMi is proud to present the 12th Annual...

Clinical Trials in CNS

The highly anticipated and respected 12th annual Clinical Trials in CNS Conference returns to London with a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers, the agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices in clinical trials. 

>>>>>Event highlights include:

Learn the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques

Discover ways to design late stage clinical trials

Overcome challenges of delivery within the CNS

Determine the legal and ethical issues behind sham surgery

KEYNOTE SPEAKERS INCLUDE:

Larry Alphs, Therapeutic Area Leader, Johnson & Johnson

Lars Bauer, Senior Medical Director TA CNS, UCB Pharma

Tom Isaacs, Co-founder, Cure Parkinson’s Trust

Kyriacos Mitrophanous, Head of Research, Oxford Biomedica

Mathieu Albasser, Post Doctoral Researcher, Eli Lilly 

Johannes Streffer, Senior Director, Experimental Medicine Europe, Janssen Research & Development

Warren Hirst, Associate Research Fellow Neurodegeneration Research, Pfizer

Eric Karran, Director of Research, Alzheimers Research UK

PLUS AN INTERACTIVE POST-CONFERENCE WORKSHOP

20TH NOVEMBER 2013 | MARRIOTT REGENTS PARK HOTEL | LONDON, UK

Defining Clinical Relevance

Workshop Leaders: Susan Mcgoldrick, Managing Director, QCTR

Audrey Jamieson, Business Development Manager, QCTR

08.30 - 12.30

**Book by 19th July 2013 and save £300**

**Book by 31st September 2013 and save £100**

Visit our website here: http://www.smi-online.co.uk/goto/clinicaltrialscns26.asp

Alternatively, contact: Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins@smi-online.co.uk

Academic & Group discounts available




Further information
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!